The Medical Letter on Drugs and Therapeutics
In Brief: Palladone Withdrawn
Download PDF:   US English
Med Lett Drugs Ther. 2005 Aug 1;47(1214):61
 Select a term to see related articles  abuse   Addiction   Analgesia   Analgesics   Avinza   chronic pain   Dilaudid   Drug abuse   Drug dependence   Duragesic   Fentanyl   Hydrocodone   Hydromorphone   Kadian   Morphine   MS Contin   opioids   Oramorph   Oramorph SR   Oxycontin   pain   Palladone 

The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3).

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article